The Latest Cardiac and Vascular News
SAN DIEGO, Sept. 27, 2022 /PRNewswire/ — REVA Medical, LLC, a leader in bioresorbable polymer technologies for vascular applications, today announced that enrollment in the MOTIV pivotal trial has been initiated at clinical centers in both the U.S. and Europe. The study will evaluate the use of the MOTIV® Sirolimus-Eluting Bioresorbable Vascular Scaffold for treatment in patients suffering from […]
SAN DIEGO, July 25, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, today announced that its MOTIV™ bioresorbable scaffold is the first drug-eluting bioresorbable scaffold to receive CE Mark approval for treatment of below the knee peripheral artery disease. Late last year, […]
